Spero Therapeutics, Inc. (SPRO) Financials

SPRO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 59.0 million 6.1 million
Dec. 31, 2025 68.9 million 9.9 million
Sept. 30, 2025 54.2 million 27.7 million
June 30, 2025 62.1 million 29.3 million

SPRO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 15.9 million 1.1 million
Dec. 31, 2025 -8.4 million 1.0 million
Sept. 30, 2025 17.4 million 1.0 million
June 30, 2025 -17.7 million 714000

SPRO Net Income

No data available :(

SPRO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 56.1 million 507000 2.5 million
Dec. 31, 2025 40.3 million - 939000
Sept. 30, 2025 48.6 million - 3.4 million
June 30, 2025 31.2 million - 3.6 million

SPRO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 57.3 million
Dec. 31, 2025 59.4 million
Sept. 30, 2025 56.3 million
June 30, 2025 56.0 million

SPRO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 2.9 million 4.9 million -
Dec. 31, 2025 - 5.6 million 4.3 million -
Sept. 30, 2025 - 8.6 million 4.2 million -
June 30, 2025 - 10.7 million 5.9 million -

SPRO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 258000 -
Dec. 31, 2025 39.7 million -
Sept. 30, 2025 3.0 million -
June 30, 2025 11.8 million -

SPRO Revenue by Segment
Graph available only for paid members. Upgrade to see it.

SPRO

Price: $2.77

52 week price:
1.80
3.22

Earnings Per Share: 0.27 USD

P/E Ratio: 9.63

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 179389

Market Capitalization: 163.3 million

Links: